Validation of the IMWG standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?

Key Points CDKN2A and TP53 deletions remain of bad prognostic value in younger MCL patients treated according to the current standard of care. CDKN2A and TP53 deletions have independent deleterious effects and should be considered for treatment decisions in addition to MIPI and Ki-67 index.

Download Full-text

The prognostic significance of inflammation-based scores in patients with ampullary carcinoma after pancreaticoduodenectomy

10.21203/rs.3.rs-23444/v2 ◽

2020 ◽

Author(s):

Shuxin Sun ◽

Chaobin He ◽

Jun Wang ◽

Xin Huang ◽

Jiali Wu ◽

...

Keyword(s):

Prognostic Value ◽

Prognostic Score ◽

Prognostic Significance ◽

Prognostic Index ◽

Glasgow Prognostic Score ◽

Prognostic Nutritional Index ◽

Significant Prognostic Factor ◽

Entire Cohort ◽

Lymphocyte Ratio ◽

Survival Differences

Abstract Background Growing evidence indicates that systemic inflammatory response plays an important role in cancer development and progression. Several inflammatory markers have been reported to be associated with the clinical outcomes in patients with various types of cancer. This study was designed to evaluate the prognostic value of the inflammatory indexes in patients suffering from ampullary cancer (AC) who underwent pancreaticoduodenectomy (PD). Methods We retrospectively reviewed a database of 358 patients with AC who underwent PD between 2009 and 2018. R software was used to compare the area under the time-dependent receiver operating characteristic (ROC) curves (AUROCs) of the inflammation-based indexes, including the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), modified Glasgow Prognostic Score (mGPS), prognostic nutritional index (PNI) and prognostic index (PI), in terms of their predictive value of survival. The survival differences of these indexes were compared by Kaplan-Meier method and univariate and multivariate analyses were performed to determine the prognostic factors of progress-free survival (PFS) and overall survival (OS). Results The estimated 1-, 2-, and 3-year OS and PFS rates were 83.9%, 65.8%, 55.2% and 58.0%, 42.8%, 37.8%, respectively, for the entire cohort. The survival differences were significant in terms of OS and PFS when they were stratified by these inflammation-based indexes. The comparisons of AUROCs of these inflammation-based indexes illustrated that NLR and PI displayed highest prognostic value, compared to other indexes. When NLR and PI were combined, NLR-PI showed even higher AUROC values and was identified as a significant prognostic factor in terms of OS and PFS. Conclusion Specific inflammatory indexes, such as NLR, PLR and PI, were found to be able to predict the OS or PFS of patients. As a novel inflammatory index, the level of NLR-PI, which can be regarded as a more useful prognostic index, exhibited strong predictive power for predicting prognosis of patients with AC after PD procedure.

Download Full-text

Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System

Blood ◽

10.1182/blood-2015-05-644039 ◽

2015 ◽

Vol 126 (17) ◽

pp. 1996-2004 ◽

Cited By ~ 53

Author(s):

Rowan Kuiper ◽

Mark van Duin ◽

Martin H. van Vliet ◽

Annemiek Broijl ◽

Bronno van der Holt ◽

...

Keyword(s):

Gene Expression ◽

Multiple Myeloma ◽

Prognostic Value ◽

Staging System ◽

Risk Classification ◽

Low Risk ◽

Key Points ◽

International Staging System

Key Points Combination of ISS and the EMC92 gene classifier is a novel clinically applicable risk classification for survival in multiple myeloma. ISS has clear independent additive prognostic value in combination with GEP classifiers or FISH markers.

Download Full-text

Comparison of Standard and CA-125 Response Criteria in Patients With Epithelial Ovarian Cancer Treated With Platinum or Paclitaxel

Journal of Clinical Oncology ◽

10.1200/jco.1999.17.2.501 ◽

1999 ◽

Vol 17 (2) ◽

pp. 501-501 ◽

Cited By ~ 83

Author(s):

John A. Bridgewater ◽

Ann E. Nelstrop ◽

Gordon J.S. Rustin ◽

Martin E. Gore ◽

William P. McGuire ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Stable Disease ◽

Progression Free Survival ◽

Response Rates ◽

Response Criteria ◽

Ca 125 ◽

Free Survival ◽

Median Progression Free Survival ◽

Standard Response

PURPOSE: To assess CA-125 as a measure of response in patients treated with paclitaxel. PATIENTS AND METHODS: One hundred forty-four patients treated with paclitaxel derived from four different trials and 625 patients treated with platinum from two trials were analyzed using precisely defined 50% and 75% reductions in CA-125. The standard and CA-125 response rates to paclitaxel and platinum were compared. In addition, we analyzed individual patient groups in which there was a difference in response according to the two response criteria. RESULTS: Patients with stable disease as determined by standard criteria who were treated with platinum and responded according to CA-125 criteria have an improved median progression-free survival compared with patients with stable disease who did not respond according to CA-125 criteria (10.6 v 4.8 months; P < .001). Standard and CA-125 response rates for patients treated with platinum (58.93% v 61.31%, respectively) and paclitaxel (30.65% v 31.67%, respectively) were very similar, as were rates of false-positive prediction of response by CA-125 (platinum 2.2% and paclitaxel 2.9%). Responders to paclitaxel had a significantly improved progression-free survival compared with nonresponders by both standard criteria (median progression-free survival, 6.8 v 2.5 months; P < .001) and CA-125 criteria (median progression-free survival, 6.8 v 3.4 months; P < .001). CONCLUSION: For assessing activity of therapy for ovarian cancer, these data show that precise 50% or 75% CA-125 response criteria are as sensitive as standard response criteria. We propose that they may be used as a measure of response in lieu of or in addition to standard response criteria in clinical trials involving epithelial ovarian cancer. Sensitivity is maintained whether patients are treated with platinum or paclitaxel.

Download Full-text

Anti–factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study

Blood ◽

10.1182/blood-2015-09-672774 ◽

2016 ◽

Vol 127 (19) ◽

pp. 2289-2297 ◽

Cited By ~ 25

Author(s):

Andreas Tiede ◽

Christoph J. Hofbauer ◽

Sonja Werwitzke ◽

Paul Knöbl ◽

Saskia Gottstein ◽

...

Keyword(s):

Factor Viii ◽

Specific Antibody ◽

Immunoglobulin G ◽

Poor Prognosis ◽

Prognostic Value ◽

Hemophilia A ◽

Acquired Hemophilia A ◽

Acquired Hemophilia ◽

Potential Marker ◽

Key Points

Key Points This study is the first to assess the prognostic value of FVIII-specific antibody data in patients with AHA. Anti-FVIII IgA, but not immunoglobulin G, autoantibodies at baseline are potential predictors of recurrence and poor outcome of AHA.

Download Full-text

Gene expression and risk of leukemic transformation in myelodysplasia

Blood ◽

10.1182/blood-2017-05-783050 ◽

2017 ◽

Vol 130 (24) ◽

pp. 2642-2653 ◽

Cited By ~ 28

Author(s):

Yusuke Shiozawa ◽

Luca Malcovati ◽

Anna Gallì ◽

Andrea Pellagatti ◽

Mohsen Karimi ◽

...

Keyword(s):

Gene Expression ◽

Prognostic Value ◽

Expression Profiles ◽

Gene Expression Profiles ◽

Transcriptomic Analysis ◽

Leukemic Transformation ◽

Key Points

Key Points Through a comprehensive transcriptomic analysis, we discovered 2 major subgroups of myelodysplasia defined by gene expression profiles. The gene expression–based subgroups had independent prognostic value, which was validated in an external cohort.

Download Full-text

Prediction of outcome using positron emission tomography (PET) compared to standard response criteria and potential role in treatment decisions in diffuse large B-cell lymphoma (DLBCL) patients

Journal of Clinical Oncology ◽

10.1200/jco.2006.24.18_suppl.7565 ◽

2006 ◽

Vol 24 (18_suppl) ◽

pp. 7565-7565

Author(s):

M. Trneny ◽

U. Jaeger ◽

O. Belohlavek ◽

C. Skrabs ◽

J. Koren ◽

...

Keyword(s):

B Cell Lymphoma ◽

Response Criteria ◽

Limited Data ◽

Lack Of Information ◽

Positron Emission ◽

Standard Response ◽

The Impact ◽

Additional Therapy ◽

Valid Information

7565 Background: PET has been demonstrated to give valid information about viable tumor residua. There are however only limited data regarding the combination of classical response criteria with PET and there is a lack of information on the impact of additional therapy (add-Th) on the outcome of PET neg. or PET pos. pts. Methods: One hundred thirty-nine pts (median age 50y) with newly diagnosed DLBCL who were examined by PET during (after 2–4 cycles CHT - ‘early PET’) or/and at the end of therapy (‘end PET’) were analyzed retrospectively. IPI risk distribution were as follows: L 28%, LI 24%, IH 33% and H 15% pts. All pts were treated with anthracyclin based CHT. “Early PET” was performed in 84 pts. and “end PET” in 103 pts before add-Th, PET at both time points was performed in 48 pts. Add-Th (HDT with ASCT or/and radiotherapy), was given as planned or as a result of response evaluation (conventional methods - CT, trephine biopsy). No treatment modification was made on PET result only, except for 2 cases when planned RT was skipped because of PET neg. RT was performed in 59 pts (42.4%) and HDT with ASCT as consolidation in 54 pts (38.8%). Median follow up was 30 m. Results: CR or CRu was achieved after CHT in 102 (74%) pts, PR in 24 (17%) pts, stable or progress dis. in 13 (9%). ‘Early PET’ was neg. in 60% pts and ‘end PET’ was neg in 67% pts. PET neg. was achieved at least once in 97 (70%) pts, and PET pos. at least once was found in 50 pts (36%). The PFS at 30 m according to the combination of conventional and PET response was as follows: for CR PET-neg. pts 89%, for PR PET-neg. pts 90%, for CR PET-pos. pts 45% and for PR PET-pos. pts 64% (p=0.0001). OS was 93%, 63%, 90% and 83%, respect.(p=0.004). The analysis of impact of add-Th showed PFS at 30 m: for PET-neg pts with Add-Th 96%, for PET-neg. pts without Add-Th 82%. PET-pos. pts without Add-Th had a PFS of only 10% and PET-pos. pts with add-Th had PFS 58% (p=0.0001). The OS was 92%, 98%, 38% and 74% respect. (p=0.0001). Conclusions: Our data demonstrate that PET give more powerful information than standard response criteria. The second analysis support the the idea that pts with DLBCL in CR who remain PET pos. should undergo the additional therapy. Partial support: Grant MSM 0021620808 No significant financial relationships to disclose.

Download Full-text